GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shedir Pharma Group SpA (MIL:SHE) » Definitions » Return-on-Tangible-Equity

Shedir Pharma Group SpA (MIL:SHE) Return-on-Tangible-Equity : 9.89% (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Shedir Pharma Group SpA Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Shedir Pharma Group SpA's annualized net income for the quarter that ended in Jun. 2024 was €3.11 Mil. Shedir Pharma Group SpA's average shareholder tangible equity for the quarter that ended in Jun. 2024 was €31.46 Mil. Therefore, Shedir Pharma Group SpA's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2024 was 9.89%.

The historical rank and industry rank for Shedir Pharma Group SpA's Return-on-Tangible-Equity or its related term are showing as below:

MIL:SHE' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 14.41   Med: 20.23   Max: 108.4
Current: 20.57

During the past 7 years, Shedir Pharma Group SpA's highest Return-on-Tangible-Equity was 108.40%. The lowest was 14.41%. And the median was 20.23%.

MIL:SHE's Return-on-Tangible-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 6.685 vs MIL:SHE: 20.57

Shedir Pharma Group SpA Return-on-Tangible-Equity Historical Data

The historical data trend for Shedir Pharma Group SpA's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shedir Pharma Group SpA Return-on-Tangible-Equity Chart

Shedir Pharma Group SpA Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial 14.41 20.23 17.52 23.94 20.10

Shedir Pharma Group SpA Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.54 40.08 9.11 32.22 9.89

Competitive Comparison of Shedir Pharma Group SpA's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Shedir Pharma Group SpA's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shedir Pharma Group SpA's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shedir Pharma Group SpA's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Shedir Pharma Group SpA's Return-on-Tangible-Equity falls into.


;
;

Shedir Pharma Group SpA Return-on-Tangible-Equity Calculation

Shedir Pharma Group SpA's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=5.699/( (26.271+30.427 )/ 2 )
=5.699/28.349
=20.10 %

Shedir Pharma Group SpA's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jun. 2024 )  (Q: Dec. 2023 )(Q: Jun. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jun. 2024 )  (Q: Dec. 2023 )(Q: Jun. 2024 )
=3.112/( (30.427+32.497)/ 2 )
=3.112/31.462
=9.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jun. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Shedir Pharma Group SpA  (MIL:SHE) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Shedir Pharma Group SpA Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Shedir Pharma Group SpA's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Shedir Pharma Group SpA Business Description

Traded in Other Exchanges
N/A
Address
95 - Piano di Sorrento, Via Bagnulo, Naples, ITA, 80063
Shedir Pharma Group SpA is engaged in manufacturing of nutraceuticals, cosmetics and medical devices. Its products are divided into four lines Shedir , Deimos, Phobos, and Menkar. The company's products include capsules, softgels, swallowable and chewable tablets, orosoluble powders, granules, oral solutions, drops for oral use, sprays for oral, sublingual and nasal use, Creams and gels for cosmetic use, and Spray for topical use.

Shedir Pharma Group SpA Headlines